23-Valent Pneumococcal Polysaccharide Vaccine Market Opportunities, Key Segments Poised for Growth
According to a new report from Intel Market Research , global 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) market was valued at USD 1.01 billion in 2025 and is projected to reach USD 2.08 billion by 2032 , growing at a robust CAGR of 11.1% during the forecast period (2025-2032). This substantial expansion is driven by the escalating global burden of pneumococcal diseases, particularly among aging populations and individuals with chronic health conditions, coupled with expanding government immunization initiatives worldwide. What is 23-Valent Pneumococcal Polysaccharide Vaccine? The 23-Valent Pneumococcal Polysaccharide Vaccine is a crucial preventive biological that protects against infections caused by Streptococcus pneumoniae , targeting the 23 most prevalent or invasive serotypes responsible for the majority of pneumococcal diseases. This vaccine is specifically indicated for adults aged 65 years and older, as well as for individuals aged 2 years and above who are...